Immune checkpoint blockade (ICB) has revolutionized the landscape of cancer treatment. Nevertheless, most cancer patients still do not respond to ICB. In this issue of Cancer Cell, Blomberg et al. illustrate a critical cooperation between T cells and eosinophils, which jointly enhance effectiveness of ICB in breast cancer.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ccell.2022.11.008 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!